What Thymosin beta-4 is
Thymosin beta-4 is an endogenous actin-binding peptide involved in cell motility, repair biology, and inflammatory context.
Thymosin beta-4 is grouped under Fitness + Recovery / Endogenous / Biology on PeptideFactCheck because it is the biological reference point behind many TB-500 recovery claims.
The useful starting point is to separate the molecule itself from the internet story around it. It is the endogenous peptide people cite when they want TB-500 to sound more established.
Why people keep looking it up
People connect it with wound healing, tissue repair, and the biological logic behind TB-500.
Thymosin beta-4 binds actin and is involved in cell movement and repair contexts.
Thymosin beta-4 tends to stay in the conversation because it touches a familiar public theme: actin sequestration, cell migration, and repair biology. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
The biology is real, but that does not automatically validate every TB-500 or recovery-product claim.
Human research exists in limited contexts, but it does not automatically validate broad internet performance claims.
Preclinical work has explored wound repair, tissue remodeling, inflammation, and cell migration.
Why this page carries the current tier: Endogenous biology plus limited human research, with many claims still extrapolated.
The current seed trail for Thymosin beta-4 is pulling from 2 databases sources and 1 literature source.
Safety, limits, and regulatory context
The biggest risk is category drift: using endogenous biology to imply unapproved product outcomes.
Thymosin beta-4 as biology is distinct from any marketed research peptide product. Check labels and trials for specific drug candidates.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Thymosin beta-4. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for Thymosin beta-4 is CID 45382195. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 45382195
- Formula
- C212H350N56O78S
- Molecular weight
- 4963
- InChIKey
- UGPMCIBIHRSCBV-UHFFFAOYSA-N
Matched synonyms include Thymosin Beta 4, THYMOSIN BETA 4 ACETATE, ([13C6]Leu17)-Thymosin b4 (human, bovine, horse, rat) trifluoroacetate salt Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-[13C6]Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH trifluoroacetate salt, Thymosin beta4 Acetate, Thymosin beta 4?, Thymosin b4 (cattle), orb1910607, AKOS034831565.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for Thymosin beta-4 returns 17 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Thymosin beta-4 returns 1201 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.